Steatosis - Revision history

Michael at 19:22, 16 May 2024

2024-05-16T19:22:38Z

← Older revision		Revision as of 19:22, 16 May 2024
Line 7:		Line 7:
	\| Micro = fatty change (macrovesicular or microvesicular and periportal or centrilobular), negative for ballooning degeneration, negative for significant inflammation - esp. [[neutrophils]]		\| Micro = fatty change (macrovesicular or microvesicular and periportal or centrilobular), negative for ballooning degeneration, negative for significant inflammation - esp. [[neutrophils]]
	\| Subtypes = macrovesicular steatosis (periportal, centrilobular), microvesicular steatosis		\| Subtypes = macrovesicular steatosis (periportal, centrilobular), microvesicular steatosis
	\| LMDDx = [[steatohepatitis]] (ASH, ~~NASH~~), [[drug-induced liver injury]]		\| LMDDx = [[steatohepatitis]] (ASH, MASH), [[drug-induced liver injury]]
	\| Stains =		\| Stains =
	\| IHC =		\| IHC =
Line 28:		Line 28:
	\| Prognosis = dependent on underlying cause		\| Prognosis = dependent on underlying cause
	\| Other =		\| Other =
	\| ClinDDx = [[ASH]], [[~~NASH~~]], [[drug-induced liver injury]]		\| ClinDDx = [[ASH]], [[MASH]], [[drug-induced liver injury]]
	\| Tx = dependent on underlying cause		\| Tx = dependent on underlying cause
	}}		}}
Line 77:		Line 77:
	Centrilobular predominant (zone III) - ''DOA'':<ref name=pcddx_steatosis/>		Centrilobular predominant (zone III) - ''DOA'':<ref name=pcddx_steatosis/>
	*[[Diabetes mellitus]].		*[[Diabetes mellitus]].
	*[[Obesity]], ~~non~~-~~alcoholic~~ steatohepatitis (~~NASH~~).		*[[Obesity]], metabolic dysfunction-associated steatohepatitis ([[MASH]]).
	*[[Alcoholic liver disease]], alcoholic steatohepatitis (ASH).		*[[Alcoholic liver disease]], alcoholic steatohepatitis (ASH).

Michael: /* Gross */

2019-09-08T10:46:54Z

Gross

← Older revision		Revision as of 10:46, 8 September 2019
Line 96:		Line 96:
	*Greasy/slippery feeling.		*Greasy/slippery feeling.
	*Enlarged.		*Enlarged.

			Note:
			*May be estimated on MRI by proton density fat fraction (PDFF).<ref name=pmid23382291>{{Cite journal \| last1 = Tang \| first1 = A. \| last2 = Tan \| first2 = J. \| last3 = Sun \| first3 = M. \| last4 = Hamilton \| first4 = G. \| last5 = Bydder \| first5 = M. \| last6 = Wolfson \| first6 = T. \| last7 = Gamst \| first7 = AC. \| last8 = Middleton \| first8 = M. \| last9 = Brunt \| first9 = EM. \| title = Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. \| journal = Radiology \| volume = 267 \| issue = 2 \| pages = 422-31 \| month = May \| year = 2013 \| doi = 10.1148/radiol.12120896 \| PMID = 23382291 }}</ref>

	==Microscopic==		==Microscopic==

Michael: tweak

2019-09-08T10:45:14Z

tweak

← Older revision		Revision as of 10:45, 8 September 2019
Line 13:		Line 13:
	\| Molecular =		\| Molecular =
	\| IF =		\| IF =
	\| Gross = yellow colour, greasy/slippery ~~feelling~~, enlarged		\| Gross = yellow colour, greasy/slippery feeling, enlarged
	\| Grossing =		\| Grossing =
	\| Staging =		\| Staging =

Michael: tweak

2019-09-08T10:45:00Z

tweak

← Older revision		Revision as of 10:45, 8 September 2019
Line 91:		Line 91:
	*Donor livers with more ''macrovescicular steatosis'' = worse outcome.		*Donor livers with more ''macrovescicular steatosis'' = worse outcome.
	**More than 30% means the liver is undesirable for [[Liver transplantation pathology\|transplantation]].<ref>STC. 6 December 2010.</ref>		**More than 30% means the liver is undesirable for [[Liver transplantation pathology\|transplantation]].<ref>STC. 6 December 2010.</ref>

			==Gross==
			*Yellow colour.
			*Greasy/slippery feeling.
			*Enlarged.

	==Microscopic==		==Microscopic==

Michael: tweak

2019-09-08T10:44:02Z

tweak

← Older revision		Revision as of 10:44, 8 September 2019
Line 24:		Line 24:
	\| Prevalence = very common		\| Prevalence = very common
	\| Bloodwork =		\| Bloodwork =
	\| Rads =		\| Rads = may be estimated by proton density fat fraction (PDFF)
	\| Endoscopy =		\| Endoscopy =
	\| Prognosis = dependent on underlying cause		\| Prognosis = dependent on underlying cause

Michael: /* Macrovesicular steatosis */

2016-01-04T03:52:33Z

Macrovesicular steatosis

← Older revision		Revision as of 03:52, 4 January 2016
Line 83:		Line 83:
	*Total parenteral nutrition (TPN).		*Total parenteral nutrition (TPN).
	*[[AIDS]].		*[[AIDS]].
	*[[Phosphorus poisoning]].		*Phosphorus poisoning.
	*Exogenous steroids.		*Exogenous steroids.
	*[[Starvation]].<ref name=pmid10600264>{{Cite journal \| last1 = Nagy \| first1 = I. \| last2 = Németh \| first2 = J. \| last3 = Lászik \| first3 = Z. \| title = Effect of L-aminocarnitine, an inhibitor of mitochondrial fatty acid oxidation, on the exocrine pancreas and liver in fasted rats. \| journal = Pharmacol Res \| volume = 41 \| issue = 1 \| pages = 9-17 \| month = Jan \| year = 2000 \| doi = 10.1006/phrs.1999.0565 \| PMID = 10600264 }}</ref>		*[[Starvation]].<ref name=pmid10600264>{{Cite journal \| last1 = Nagy \| first1 = I. \| last2 = Németh \| first2 = J. \| last3 = Lászik \| first3 = Z. \| title = Effect of L-aminocarnitine, an inhibitor of mitochondrial fatty acid oxidation, on the exocrine pancreas and liver in fasted rats. \| journal = Pharmacol Res \| volume = 41 \| issue = 1 \| pages = 9-17 \| month = Jan \| year = 2000 \| doi = 10.1006/phrs.1999.0565 \| PMID = 10600264 }}</ref>

Michael at 03:31, 4 January 2016

2016-01-04T03:31:03Z

← Older revision		Revision as of 03:31, 4 January 2016
Line 28:		Line 28:
	\| Prognosis = dependent on underlying cause		\| Prognosis = dependent on underlying cause
	\| Other =		\| Other =
	\| ClinDDx = [[ASH]], [[NASH]]		\| ClinDDx = [[ASH]], [[NASH]], [[drug-induced liver injury]]
	\| Tx = dependent on underlying cause		\| Tx = dependent on underlying cause
	}}		}}

Michael at 03:29, 4 January 2016

2016-01-04T03:29:49Z

← Older revision		Revision as of 03:29, 4 January 2016
Line 31:		Line 31:
	\| Tx = dependent on underlying cause		\| Tx = dependent on underlying cause
	}}		}}
	'''Steatosis''', also '''fatty liver''', is a fatty change in the liver associated with a number of underlying causes.		'''Steatosis''', also '''fatty liver''', is a fatty change in the [[liver]] associated with a number of underlying (medical) causes.

	==General==		==General==
Line 113:		Line 113:
	==See also==		==See also==
	*[[Steatohepatitis]].		*[[Steatohepatitis]].
			*[[Medical liver disease]].

	==References==		==References==

Michael at 03:27, 4 January 2016

2016-01-04T03:27:58Z

← Older revision		Revision as of 03:27, 4 January 2016
Line 6:		Line 6:
	\| Synonyms = fatty liver		\| Synonyms = fatty liver
	\| Micro = fatty change (macrovesicular or microvesicular and periportal or centrilobular), negative for ballooning degeneration, negative for significant inflammation - esp. [[neutrophils]]		\| Micro = fatty change (macrovesicular or microvesicular and periportal or centrilobular), negative for ballooning degeneration, negative for significant inflammation - esp. [[neutrophils]]
	\| Subtypes = macrovesicular steatosis (periportal, centrilobular), microvesicular steatosis.		\| Subtypes = macrovesicular steatosis (periportal, centrilobular), microvesicular steatosis
	\| LMDDx = [[steatohepatitis]] (ASH, NASH), [[drug-induced liver injury]]		\| LMDDx = [[steatohepatitis]] (ASH, NASH), [[drug-induced liver injury]]
	\| Stains =		\| Stains =

Michael: tweak

2016-01-04T03:26:40Z

tweak

← Older revision		Revision as of 03:26, 4 January 2016
Line 3:		Line 3:
	\| Image = Non-alcoholic fatty liver disease1.jpg		\| Image = Non-alcoholic fatty liver disease1.jpg
	\| Width =		\| Width =
	\| Caption = Steatosis. Elastic [[Masson's trichrome]].		\| Caption = Steatosis. Elastic [[Masson's trichrome stain]].
	\| Synonyms = fatty liver		\| Synonyms = fatty liver
	\| Micro = fatty change (macrovesicular or microvesicular and periportal or centrilobular), negative for ballooning degeneration, negative for significant inflammation - esp. [[neutrophils]]		\| Micro = fatty change (macrovesicular or microvesicular and periportal or centrilobular), negative for ballooning degeneration, negative for significant inflammation - esp. [[neutrophils]]
Line 62:		Line 62:
	*Hepatitis D.		*Hepatitis D.
	*Weird stuff:		*Weird stuff:
	**Congenital defects of fatty acid beta oxidation,		**Congenital defects of fatty acid beta oxidation.
	**Cholesterol ester storage disease,		**Cholesterol ester storage disease.
	**Wolman disease and Alpers syndrome.		**Wolman disease and Alpers syndrome.

Line 77:		Line 77:
	Centrilobular predominant (zone III) - ''DOA'':<ref name=pcddx_steatosis/>		Centrilobular predominant (zone III) - ''DOA'':<ref name=pcddx_steatosis/>
	*[[Diabetes mellitus]].		*[[Diabetes mellitus]].
	*Obesity, non-alcoholic steatohepatitis (NASH).		*[[Obesity]], non-alcoholic steatohepatitis (NASH).
	*Alcoholic liver disease, alcoholic steatohepatitis (ASH).		*[[Alcoholic liver disease]], alcoholic steatohepatitis (ASH).

	Periportal predominant (zone I) - ''TAPES'':<ref name=pcddx_steatosis/>		Periportal predominant (zone I) - ''TAPES'':<ref name=pcddx_steatosis/>
	*Total parenteral nutrition (TPN).		*Total parenteral nutrition (TPN).
	*[[AIDS]].		*[[AIDS]].
	*Phosphorus poisoning.		*[[Phosphorus poisoning]].
	*Exogenous steroids.		*Exogenous steroids.
	*[[Starvation]].<ref name=pmid10600264>{{Cite journal \| last1 = Nagy \| first1 = I. \| last2 = Németh \| first2 = J. \| last3 = Lászik \| first3 = Z. \| title = Effect of L-aminocarnitine, an inhibitor of mitochondrial fatty acid oxidation, on the exocrine pancreas and liver in fasted rats. \| journal = Pharmacol Res \| volume = 41 \| issue = 1 \| pages = 9-17 \| month = Jan \| year = 2000 \| doi = 10.1006/phrs.1999.0565 \| PMID = 10600264 }}</ref>		*[[Starvation]].<ref name=pmid10600264>{{Cite journal \| last1 = Nagy \| first1 = I. \| last2 = Németh \| first2 = J. \| last3 = Lászik \| first3 = Z. \| title = Effect of L-aminocarnitine, an inhibitor of mitochondrial fatty acid oxidation, on the exocrine pancreas and liver in fasted rats. \| journal = Pharmacol Res \| volume = 41 \| issue = 1 \| pages = 9-17 \| month = Jan \| year = 2000 \| doi = 10.1006/phrs.1999.0565 \| PMID = 10600264 }}</ref>
Line 108:		Line 108:
	<gallery>		<gallery>
	Image:Periportal_hepatosteatosis_intermed_mag.jpg \| Periportal steatosis. (WC/Nephron)		Image:Periportal_hepatosteatosis_intermed_mag.jpg \| Periportal steatosis. (WC/Nephron)
	~~</gallery>~~
	~~Image:~~
	~~<gallery>~~
	Image:Non-alcoholic_fatty_liver_disease1.jpg \| Centrilobular steatosis. (WC/Nephron)		Image:Non-alcoholic_fatty_liver_disease1.jpg \| Centrilobular steatosis. (WC/Nephron)
	</gallery>		</gallery>